We scan new podcasts and send you the top 5 insights daily.
Greg Crescenzi says Addgene holds historical, curated information that no one else has and is talking with software and AI companies about partnerships. He sees AI today as rapidly changing the space and wants Addgene's archive to support new data and information products, he says.
Malina Fan spent months trying to get plasmids, then realized depositing scientists wanted to share but lacked time and infrastructure. Greg Crescenzi says Addgene took over storage, logistics, legal agreements, QC, and curation, removing the burden from both requesters and institutions shipping materials so sharing could scale.
The power of AI for Novonesis isn't the algorithm itself, but its application to a massive, well-structured proprietary dataset. Their organized library of 100,000 strains allows AI to rapidly predict protein shapes and accelerate R&D in ways competitors cannot match.
Greg Crescenzi says 90% of Addgene's COVID deposits and resources were made available to industry during the pandemic, enabling a faster collective response. Addgene now wants to extend that same industry access to much of its other translational material, not just crisis-specific reagents, according to him.
Long before the AI boom, Novonesis began creating structured data repositories in the 2000s to manage high-throughput screening data. This decades-long data discipline is now a massive competitive advantage, providing the clean foundation necessary for effective machine learning and digital twins.
Chai Discovery's partnership with Eli Lilly involves building a custom foundation model trained on Lilly's unique historical data. This signals a new collaboration model where AI firms act as specialized infrastructure builders, creating proprietary, data-moated AI for large pharmaceutical companies.
AI's potential in drug discovery is contingent on having a robust "data factory" to generate massive, high-quality biological datasets. Najat Khan emphasizes that the combination of this data infrastructure, AI, supercomputing, and human expertise is what creates a true competitive advantage, not the algorithm alone.
InduPro's AI advantage isn't a better algorithm but a superior, proprietary dataset generated in-house. This high-quality data, combining proximity maps with protein quantification, is the true differentiator that their tailor-made AI tools interrogate, avoiding reliance on public data.
The traditional transactional model where AI companies purchase pharma data is ending. To resolve the stalemate where AI needs trial data and trials need validated AI, the industry is shifting to strategic partnerships. In these collaborations, both parties jointly generate evidence during trials, accelerating development and providing mutual benefit.
Greg Crescenzi says Addgene's Solid Bio deal brings a therapeutic company's technology to academic and industry labs. Addgene already sells NEB and Promega products and wants more such partnerships, making reagent sharing flow from industry to academia as well as the reverse, according to him.
Regeneron Genetics Center's edge in AI drug discovery comes not just from its massive database, but from 14 years of interpreting high-quality, multimodal data (genomics linked to health records). This deep understanding is crucial for training reliable AI models and deriving accurate biological insights, a lesson for all life science data platforms.